Phase II Study of RFS 2000 in Relapsed NSCLC
OBJECTIVES: I. Determine the response rate, time to progression and overall survival of
patients with recurrent non-small cell lung cancer when treated with nitrocamptothecin. II.
Assess the toxicities and pharmacokinetics of this regimen in these patients.
OUTLINE: Patients receive oral nitrocamptothecin daily on days 1-5. Treatment continues
weekly in the absence of disease progression or unacceptable toxicity. Patients are followed
PROJECTED ACCRUAL: A total of 20-55 patients will be accrued for this study.
Primary Purpose: Treatment
Show-Li Sun, MD
United States: Federal Government
|SuperGen, Incorporated||Dublin, California 94568|